Thanks for the speedy response BDAZ!

That helps a lot.

"I am a little skeptical of the 9.5% annual MACE rate shown on slide 16 for ACS patients with diabetes. In no ACS/diabetes CVOT trial that I've seen has the annual event rate exceeded the ~8% observed in EXAMINE (described above). I agree that the low HDL requirement of BETonMACE should push the event rate higher than that observed in previous ACS/diabetes CVOT trials. However, it is not clear to me from those references on slide 16 how Resverlogix arrived at those numbers shown on slide 16. Perhaps slide 16 includes not just 3-point MACE but other "soft" MACE in those calculations."


Any chance that you have this presentation handy?

Thanks,
Pomp